Cargando…
MiR-525-5p inhibits diffuse large B cell lymphoma progression via the Myd88/NF-κB signaling pathway
Diffuse large B-cell lymphoma (DLBCL) is a B-cell lymphoma with a high degree of aggressiveness. Recently, evidence has shown that miR-525-5p is decreased in DLBCL, suggesting its possible involvement in tumor progression. In this study, miR-525-5p suppressed proliferation, invasion and clonogenicit...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PeerJ Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634338/ https://www.ncbi.nlm.nih.gov/pubmed/37953776 http://dx.doi.org/10.7717/peerj.16388 |
_version_ | 1785132808561229824 |
---|---|
author | Guo, Xiuchen Zhang, Jingbo Zeng, Jingya Guo, Yiwei Zhao, Lina |
author_facet | Guo, Xiuchen Zhang, Jingbo Zeng, Jingya Guo, Yiwei Zhao, Lina |
author_sort | Guo, Xiuchen |
collection | PubMed |
description | Diffuse large B-cell lymphoma (DLBCL) is a B-cell lymphoma with a high degree of aggressiveness. Recently, evidence has shown that miR-525-5p is decreased in DLBCL, suggesting its possible involvement in tumor progression. In this study, miR-525-5p suppressed proliferation, invasion and clonogenicity, and increased apoptosis of U2932 cells, whereas miR-525-5p silencing enhanced tumor cell growth. Next, miR-525-5p targets the 3′-UTR of Myd88, and Myd88 protein was increased in lymphoma tissues. Similar to the miR-525-5p mimic, Myd88 siRNA suppressed proliferation, invasion, and clonogenicity, and enhanced apoptosis of U2932 cells. We observed that Myd88 reversed the inhibitory effect of miR-525-5p on tumor cell growth by transfecting cells with miR-525-5p mimics alone or together with Myd88 overexpression vector. In addition, in vivo studies have shown that compared to the control group, U2932 cells with upregulated miR-525-5p expression have a reduced ability to induce tumor formation. In conclusion, our results demonstrate that miR-525-5p inhibits the progression of DLBCL through the Myd88/NF-κB pathway, which largely fills the gap of previous studies, and our results may provide a new reference for the targeted treatment of DLBCL. |
format | Online Article Text |
id | pubmed-10634338 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | PeerJ Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106343382023-11-10 MiR-525-5p inhibits diffuse large B cell lymphoma progression via the Myd88/NF-κB signaling pathway Guo, Xiuchen Zhang, Jingbo Zeng, Jingya Guo, Yiwei Zhao, Lina PeerJ Biochemistry Diffuse large B-cell lymphoma (DLBCL) is a B-cell lymphoma with a high degree of aggressiveness. Recently, evidence has shown that miR-525-5p is decreased in DLBCL, suggesting its possible involvement in tumor progression. In this study, miR-525-5p suppressed proliferation, invasion and clonogenicity, and increased apoptosis of U2932 cells, whereas miR-525-5p silencing enhanced tumor cell growth. Next, miR-525-5p targets the 3′-UTR of Myd88, and Myd88 protein was increased in lymphoma tissues. Similar to the miR-525-5p mimic, Myd88 siRNA suppressed proliferation, invasion, and clonogenicity, and enhanced apoptosis of U2932 cells. We observed that Myd88 reversed the inhibitory effect of miR-525-5p on tumor cell growth by transfecting cells with miR-525-5p mimics alone or together with Myd88 overexpression vector. In addition, in vivo studies have shown that compared to the control group, U2932 cells with upregulated miR-525-5p expression have a reduced ability to induce tumor formation. In conclusion, our results demonstrate that miR-525-5p inhibits the progression of DLBCL through the Myd88/NF-κB pathway, which largely fills the gap of previous studies, and our results may provide a new reference for the targeted treatment of DLBCL. PeerJ Inc. 2023-11-06 /pmc/articles/PMC10634338/ /pubmed/37953776 http://dx.doi.org/10.7717/peerj.16388 Text en © 2023 Guo et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited. |
spellingShingle | Biochemistry Guo, Xiuchen Zhang, Jingbo Zeng, Jingya Guo, Yiwei Zhao, Lina MiR-525-5p inhibits diffuse large B cell lymphoma progression via the Myd88/NF-κB signaling pathway |
title | MiR-525-5p inhibits diffuse large B cell lymphoma progression via the Myd88/NF-κB signaling pathway |
title_full | MiR-525-5p inhibits diffuse large B cell lymphoma progression via the Myd88/NF-κB signaling pathway |
title_fullStr | MiR-525-5p inhibits diffuse large B cell lymphoma progression via the Myd88/NF-κB signaling pathway |
title_full_unstemmed | MiR-525-5p inhibits diffuse large B cell lymphoma progression via the Myd88/NF-κB signaling pathway |
title_short | MiR-525-5p inhibits diffuse large B cell lymphoma progression via the Myd88/NF-κB signaling pathway |
title_sort | mir-525-5p inhibits diffuse large b cell lymphoma progression via the myd88/nf-κb signaling pathway |
topic | Biochemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634338/ https://www.ncbi.nlm.nih.gov/pubmed/37953776 http://dx.doi.org/10.7717/peerj.16388 |
work_keys_str_mv | AT guoxiuchen mir5255pinhibitsdiffuselargebcelllymphomaprogressionviathemyd88nfkbsignalingpathway AT zhangjingbo mir5255pinhibitsdiffuselargebcelllymphomaprogressionviathemyd88nfkbsignalingpathway AT zengjingya mir5255pinhibitsdiffuselargebcelllymphomaprogressionviathemyd88nfkbsignalingpathway AT guoyiwei mir5255pinhibitsdiffuselargebcelllymphomaprogressionviathemyd88nfkbsignalingpathway AT zhaolina mir5255pinhibitsdiffuselargebcelllymphomaprogressionviathemyd88nfkbsignalingpathway |